Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Menopause Health Center

Font Size

Dramatic Drop in Hormone Therapy Use

Results of Clinical Trial Convince Many Women to Abandon Hormone Therapy After Menopause
WebMD Health News

Jan. 6, 2004 -- New research confirms that millions of women in the U.S. have abandoned menopausal hormone therapy, but other recent studies suggest that many are having a difficult time coping without it.

Stanford University researchers report that prescriptions for the estrogen-plus-progestin drug Prempro declined by two-thirds in the year following the early termination of a large prevention trial linking Prempro's use in postmenopausal women to an increased risk of heart attacks, blood clots, and breast cancer.

Roughly 2 1/2 million women in the U.S. still take estrogen-plus-progestin combinations like Prempro, compared with 6 million who took the hormone therapy before July of 2002, says lead investigator Randall S. Stafford, MD, PhD, of the Stanford Prevention Research Center. That is when government health officials announced plans to halt the Women's Health Initiative (WHI) study evaluating the combination treatment for the prevention of heart disease and other diseases associated with aging.

A WHI trial evaluating estrogen therapy alone, which is given to women who have had hysterectomies, is scheduled to end in 2005. But the new findings also show a steep decline in its use. Prescriptions for the estrogen-alone drug Premarin dropped by one-third in the year following the cessation of the Prempro trial.


Stafford and colleagues used two national databases to assess trends in menopausal hormone therapy usage between January 1995 and July 2003. Annual prescriptions for these drugs increased from 58 million in 1995 to 90 million in 1999, then remained relatively stable until the WHI trial was stopped in July of 2002. A year later, HRT prescriptions had dropped to roughly 57 million. The findings are reported in the Jan. 7 issue of The Journal of the American Medical Association.

Last month, University of California researchers reported that about a quarter of the women in their study who stopped taking menopausal hormone therapy ended up going back on the treatment to relieve hot flashes and other menopausal symptoms. Other studies have also shown that many women who abandoned these medications are going back to it. It is estimated that 10 million women in the U.S. now take either estrogen alone or estrogen plus progestin.

Today on WebMD

woman walking outdoors
How to handle headaches, night sweats, and more.
mature woman holding fan in face
Symptoms and treatments.
woman hiding face behind hands
11 ways to keep skin bright and healthy.
Is it menopause or something else?
senior couple
mature woman shopping for produce
Alcohol Disrupting Your Sleep
mature couple on boat
mature woman tugging on her loose skin
senior woman wearing green hat
estrogen gene

WebMD Special Sections